{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:20:45Z","timestamp":1791829245583,"version":"4.3.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,7,12]],"date-time":"2018-07-12T00:00:00Z","timestamp":1531353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Rockwell Medical Inc.","award":["RMFPC-11"],"award-info":[{"award-number":["RMFPC-11"]}]},{"name":"Rockwell Medical Inc.","award":["RMFPC-11"],"award-info":[{"award-number":["RMFPC-11"]}]},{"name":"Rockwell Medical Inc.","award":["RMFPC-11"],"award-info":[{"award-number":["RMFPC-11"]}]},{"name":"Rockwell Medical Inc","award":["RMFPC-11"],"award-info":[{"award-number":["RMFPC-11"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s00467-018-4014-3","type":"journal-article","created":{"date-parts":[[2018,7,12]],"date-time":"2018-07-12T15:43:40Z","timestamp":1531410220000},"page":"2151-2159","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Pharmacokinetics of ferric pyrophosphate citrate administered via dialysate and intravenously to pediatric patients on chronic hemodialysis"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8143-1106","authenticated-orcid":false,"given":"Raymond D.","family":"Pratt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Grimberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua J.","family":"Zaritsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley A.","family":"Warady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,12]]},"reference":[{"key":"4014_CR1","unstructured":"KDOQI (2006) III. Clinical practice recommendations for anemia in chronic kidney disease in children. Am J Kidney Dis 47:S86\u2013S108"},{"key":"4014_CR2","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1152\/physrev.00008.2013","volume":"93","author":"T Ganz","year":"2013","unstructured":"Ganz T (2013) Systemic iron homeostasis. Physiol Rev 93:1721\u20131741","journal-title":"Physiol Rev"},{"key":"4014_CR3","first-page":"108","volume":"73","author":"NC Weerd van der","year":"2015","unstructured":"van der Weerd NC, Grooteman MP, Nube MJ, ter Wee PM, Swinkels DW, Gaillard CA (2015) Hepcidin in chronic kidney disease: not an anaemia management tool, but promising as a cardiovascular biomarker. Neth J Med 73:108\u2013118","journal-title":"Neth J Med"},{"key":"4014_CR4","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.2215\/CJN.05931108","volume":"4","author":"J Zaritsky","year":"2009","unstructured":"Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G, Nemeth E, Ganz T, Rivera S, Nissenson AR, Salusky IB (2009) Hepcidin\u2014a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 4:1051\u20131056","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"4014_CR5","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1681\/ASN.2014090922","volume":"26","author":"DM Charytan","year":"2015","unstructured":"Charytan DM, Pai AB, Chan CT, Coyne DW, Hung AM, Kovesdy CP, Fishbane S (2015) Considerations and challenges in defining optimal iron utilization in hemodialysis. J Am Soc Nephrol 26(6):1238\u20131247","journal-title":"J Am Soc Nephrol"},{"key":"4014_CR6","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1093\/ndt\/gft062","volume":"28","author":"GR Bailie","year":"2013","unstructured":"Bailie GR, Larkina M, Goodkin DA, Li Y, Pisoni RL, Bieber B, Mason N, Tong L, Locatelli F, Marshall MR, Inaba M, Robinson BM (2013) Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 28:2570\u20132579","journal-title":"Nephrol Dial Transplant"},{"key":"4014_CR7","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.2215\/CJN.02600315","volume":"10","author":"A Karaboyas","year":"2015","unstructured":"Karaboyas A, Zee J, Morgenstern H, Nolen JG, Hakim R, Kalantar-Zadeh K, Zager P, Pisoni RL, Port FK, Robinson BM (2015) Understanding the recent increase in ferritin levels in United States dialysis patients: potential impact of changes in intravenous iron and erythropoiesis-stimulating agent dosing. Clin J Am Soc Nephrol 10:1814\u20131821","journal-title":"Clin J Am Soc Nephrol"},{"key":"4014_CR8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.kint.2015.10.002","volume":"89","author":"IC Macdougall","year":"2016","unstructured":"Macdougall IC, Bircher AJ, Eckardt KU, Obrador GT, Pollock CA, Stenvinkel P, Swinkels DW, Wanner C, Weiss G, Chertow GM (2016) Iron management in chronic kidney disease: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference. Kidney Int 89:28\u201339","journal-title":"Kidney Int"},{"key":"4014_CR9","doi-asserted-by":"publisher","first-page":"188","DOI":"10.5414\/CN107266","volume":"77","author":"N Singh","year":"2012","unstructured":"Singh N, Agarwal AK (2012) Pumping iron: revisiting risks, benefits and strategies in treatment of iron deficiency in end-stage renal disease. Clin Nephrol 77:188\u2013194","journal-title":"Clin Nephrol"},{"key":"4014_CR10","unstructured":"Gupta A, Mishra B, Handelman GJ, Crumbliss AL, Pratt R (2015) Structural, physical and functional characterization of ferric pyrophosphate citrate (FPC, Triferic), a novel iron compound for pharmaceutical applications. Nephrol Dial Transplant 30:iii299"},{"key":"4014_CR11","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1046\/j.1523-1755.1999.00436.x","volume":"55","author":"A Gupta","year":"1999","unstructured":"Gupta A, Amin NB, Besarab A, Vogel SE, Divine GW, Yee J, Anandan JV (1999) Dialysate iron therapy: infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis. Kidney Int 55:1891\u20131898","journal-title":"Kidney Int"},{"key":"4014_CR12","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1067\/mlc.2000.110368","volume":"136","author":"A Gupta","year":"2000","unstructured":"Gupta A, Crumbliss AL (2000) Treatment of iron deficiency anemia: are monomeric iron compounds suitable for parenteral administration? J Lab Clin Med 136:371\u2013378","journal-title":"J Lab Clin Med"},{"key":"4014_CR13","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/jcph.819","volume":"57","author":"RD Pratt","year":"2017","unstructured":"Pratt RD, Swinkels DW, Ikizler TA, Gupta A (2017) Pharmacokinetics of ferric pyrophosphate citrate, a novel iron salt, administered intravenously to healthy volunteers. J Clin Pharmacol 57:312\u2013320","journal-title":"J Clin Pharmacol"},{"key":"4014_CR14","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1093\/ndt\/gfv277","volume":"30","author":"SN Fishbane","year":"2015","unstructured":"Fishbane SN, Singh AK, Cournoyer SH, Jindal KK, Fanti P, Guss CD, Lin VH, Pratt RD, Gupta A (2015) Ferric pyrophosphate citrate (Triferic) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients. Nephrol Dial Transplant 30:2019\u20132026","journal-title":"Nephrol Dial Transplant"},{"key":"4014_CR15","unstructured":"Pratt, RD and Gupta, A (2017) Pharmacokinetics of Triferic administered IV and via dialysate. NKF Spring Clinical Meetings 2017 Abstract #172; https:\/\/archive.aievolution.com\/2017\/nkf1701\/index.cfm?do=abs.viewAbs&abs=1211"},{"key":"4014_CR16","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/ki.2015.203","volume":"88","author":"A Gupta","year":"2015","unstructured":"Gupta A, Lin V, Guss C, Pratt R, Ikizler TA, Besarab A (2015) Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients. Kidney Int 88:1187\u20131194","journal-title":"Kidney Int"},{"key":"4014_CR17","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S0272-6386(03)00533-X","volume":"42","author":"M Rao","year":"2003","unstructured":"Rao M, Muirhead N, Klarenbach S, Moist L, Lindsay RM (2003) Management of anemia with quotidian hemodialysis. Am J Kidney Dis 42:18\u201323","journal-title":"Am J Kidney Dis"},{"key":"4014_CR18","doi-asserted-by":"publisher","first-page":"710","DOI":"10.7326\/0003-4819-87-6-710","volume":"87","author":"JW Eschbach","year":"1977","unstructured":"Eschbach JW, Cook JD, Scribner BH, Finch CA (1977) Iron balance in hemodialysis patients. Ann Intern Med 87:710\u2013713","journal-title":"Ann Intern Med"},{"key":"4014_CR19","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ekir.2017.11.012","volume":"3","author":"J Rottembourg","year":"2018","unstructured":"Rottembourg J (2018) Other estimation of blood losses in hemodialysis and formula for translating liver iron concentration from iron balance calculation based on iron removal by phlebotomy. Kidney Int Rep 3:220","journal-title":"Kidney Int Rep"},{"key":"4014_CR20","first-page":"481","volume":"8","author":"DE M\u00fcller-Wiefel","year":"1977","unstructured":"M\u00fcller-Wiefel DE, Sinn H, Gilli G, Scharer K (1977) Hemolysis and blood loss in children with chronic renal failure. Clin Nephrol 8:481\u2013486","journal-title":"Clin Nephrol"},{"key":"4014_CR21","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/clinchem\/25.5.741","volume":"25","author":"D Ellis","year":"1979","unstructured":"Ellis D (1979) Serum ferritin compared with other indices of iron status in children and teenagers undergoing maintenance hemodialysis. Clin Chem 25:741\u2013744","journal-title":"Clin Chem"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-018-4014-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-018-4014-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-018-4014-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T19:08:52Z","timestamp":1604603332000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-018-4014-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,12]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["4014"],"URL":"https:\/\/doi.org\/10.1007\/s00467-018-4014-3","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,12]]},"assertion":[{"value":"9 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocol and informed consent and assent documents were approved by an institutional review board for each participating site before any patients were enrolled in the study at the respective site. Written informed consent was obtained from each patient\u2019s parent or legal guardian, and if applicable, assent was obtained from the patient before any study-related procedures were performed.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Pratt and Ms. Grimberg are employees of Rockwell Medical, the sponsor of the study. Dr. Pratt holds stock in and serves on the scientific advisory board for Rockwell Medical. Dr. Zaritsky and Dr. Warady received research grants from Rockwell Medical during the conduct of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}